

## Dear Colleagues and Guests

The field of preclinical and clinical lymphoma research has seen a dramatic acceleration of progress during the last years, ranging from a molecular characterization of the disease to the development of novel mouse models, as well as preclinical drug development, ultimately culminating in massive advances in our current treatment algorithms, now involving CAR-T cells, various novel (bispecific) antibodies and new small molecule compounds.

In parallel to these scientific developments, within the state of Northrhine-Westphalia, the large comprehensive cancer centers CIO-ABCD (Aachen, Bonn, Cologne, Düsseldorf) and WTZ-EM (Essen, Münster) have strategically strengthened their collaboration, particularly through the establishment of the National Cancer Center West NCT-West (Essen, Cologne), and have further consolidated and expanded their clinical and translational lymphoma programs.

Given these developments, we are excited to launch the bi-annual West German Lymphoma Symposium, to facilitate the scientific exchange within the region, excite young researchers for lymphoma research, and, most importantly, to further expand our international visibility and outreach.

The organizing team of the West German Lymphoma Symposium is happy to invite you to be part of our inaugural meeting. The meeting will take place on 24th and 25th of May 2024 in Essen, Germany at the heart of the Ruhrgebiet.

We would be absolutely thrilled if you could join us for this event. You are cordially invited to submit an Abstract. There will be short talks selected from the best abstracts, as well as poster awards.

With all our best wishes and warm regards  
Conference chair

**Christian Reinhardt, Prof. Dr**

**Bastian v. Tresckow, Prof. Dr**

**Ralf Küppers, Prof. Dr**

University Hospital Essen, West German Cancer Center

**Peter Borchmann, Prof. Dr**

University Hospital Cologne, Clinic for Internal Medicine  
Oncology/ Haematology

**Sascha Dietrich, Prof. Dr**

University Hospital Düsseldorf  
Clinic for Haematology, Oncology and Clinical Immunology

## Under the auspices of

### Scientific lead and response for the programme



Department of Haematology and Stem Cell Transplantation  
West German Cancer Center  
University Hospital Essen (AöR)  
Hufelandstraße 55, 45147 Essen (Germany)

### Meeting Office / Organizer and Contact

CSi Hamburg GmbH  
Goernestraße 30, 20249 Hamburg (Germany)  
+49 40 30770300  
meetings@csihamburg.de



### Venue

Conference Center Essen  
Huysenallee 55  
45128 Essen (Germany)  
Nordrhein-Westfalen (NRW)



### Hybrid Event

### In co-operation with



**Start your registration**  
<https://www.lymphoma-symposium.de>



CLINIC MEETS BIOLOGY

# WEST GERMAN LYMPHOMA SYMPOSIUM

[www.lymphoma-symposium.de](http://www.lymphoma-symposium.de)

24<sup>th</sup> and 25<sup>th</sup> May 2024

Conference Center Essen (Germany)

PRELIMINARY PROGRAMME

**DAY 1** **FRIDAY, 24<sup>th</sup> MAY 2024**

from 09:30	Registration
10:45	Welcome Scientific committee
<b>11:00-1:00</b>	<b>Session 1</b> <b>The germinal center reaction as a catalyst for lymphoma development</b> Christian Reinhardt, University Hospital Essen (GER)
Chair	
<b>11:00</b>	<b>Role of Super-enhancer Hypermutation in the Pathogenesis of Diffuse Large B cell Lymphoma</b> Riccardo Dalla-Favera, Columbia University New York (USA)
<b>11:25</b>	<b>Genetics-driven epigenetic disruption of the germinal center program in B cell lymphomas</b> Laura Pasqualucci, Columbia University New York (USA)
<b>11:50</b>	<b>Aspects of Hodgkin lymphoma biology</b> Ralf Küppers, University Hospital Essen (GER)
<b>12:15</b>	<b>Modelling Sporadic Oncogenic Events in Lymphomagenesis</b> Dinis Calado, The Francis Crick Institute London (UK)
<b>12:40</b>	<b>Short talk I</b> tba
<b>12:50</b>	<b>Discussion</b>
<b>1:00-2:00</b>	<b>Break</b>
<b>2:00-4:00</b>	<b>Session 2</b> <b>Epigenetic rewiring as a driver and target of lymphomagenesis</b> Peter Borchmann, University Hospital Cologne (GER)
Chair	
<b>2:00</b>	<b>Mechanisms and therapeutic targeting of the malignant immune system</b> Ari M. Melnick, Weill Cornell Medicine New York (USA)
<b>2:25</b>	<b>Development of small molecules for epigenetic targets</b> Stefan Knapp, Goethe-University Frankfurt (GER)
<b>2:50</b>	<b>Harnessing state switches in aggressive B-cell lymphoma</b> Clemens Schmitt, Charité - University Hospital Berlin (GER)
<b>3:15</b>	<b>DNA-methylation based classification of lymphomas: A tool to come?</b> Reiner Siebert, Ulm University Hospital (GER)
<b>3:40</b>	<b>Short talk II</b> tba
<b>3:50</b>	<b>Discussion</b>
<b>4:00-6:00</b>	<b>Poster presentation and Get-together</b>

**DAY 2** **SATURDAY, 25<sup>th</sup> MAY 2024**

<b>8:00-10:00</b>	<b>Session 3</b> <b>Genetic rewiring encodes actionable vulnerabilities in lymphoma</b> Sascha Dietrich, University Hospital Düsseldorf (GER)
Chair	
<b>8:00</b>	<b>Genetic bases of immune evasion in lymphoma</b> Margaret Shipp, Dana Farber/Harvard Cancer Center Boston (USA)
<b>8:25</b>	<b>Curing aggressive lymphomas with aggressive combinations of targeted agents</b> Louis Staudt, National Cancer Institute Bethesda (USA)
<b>8:50</b>	<b>Actionable Alterations in LBCL</b> Björn Chapuy, Charité University Medicine Berlin (GER)
<b>9:15</b>	<b>Elucidation of Lymphoma Proteogenotypes</b> Thomas Oellerich, University Hospital Frankfurt (GER)
<b>9:40</b>	<b>Short talk III</b> tba
<b>9:50</b>	<b>Discussion</b>
<b>10:00-10:30</b>	<b>Break</b>
<b>10:30-12:30</b>	<b>Session 4</b> <b>The next frontier: harnessing the immune system for lymphoma therapy</b> Bastian von Tresckow, University Hospital Essen (GER)
Chair	
<b>10:30</b>	<b>Chemotherapy free approaches in first line LBCL - a dream or a reality?</b> Jason Westin, University of Texas MD Anderson Cancer Center Houston (USA)
<b>10:50</b>	<b>Enhancing immunotherapies for germinal center-derived B cell lymphomas by EZH2 inhibition</b> Wendy Béguelin, Weill Cornell Medicine New York, (USA)
<b>11:10</b>	<b>tba</b> Peter Borchmann, University Hospital Cologne (GER)
<b>11:30</b>	<b>tba</b> Elisabeth Budde, City of Hope National Medical Center Duarte (USA)
<b>11:50</b>	<b>Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities</b> Sascha Dietrich, University Hospital Düsseldorf (GER)
<b>12:10</b>	<b>Discussion</b>
<b>12:30-1:30</b>	<b>Break</b>

<b>1:30-3:00</b>	<b>Session 5</b> <b>Mechanisms of resistance and definition of high-risk DLBCL</b> Ralf Küppers, University Hospital Essen (GER)
Chair	
<b>1:30</b>	<b>tba</b> Ash A. Alizadeh, Stanford University / Stanford Comprehensive Cancer Center (USA)
<b>1:50</b>	<b>Mechanisms of resistance and definition of high-risk DLBCL</b> Andrew Davies, Southampton General Hospital (UK)
<b>2:10</b>	<b>Overcoming therapy resistance through single-cell functional precision medicine approaches</b> Philipp Staber, Medical University of Vienna (AUT)
<b>2:30</b>	<b>Autochthonous mouse models of DLBCL enable in vivo genetic screening and serve as a platform for preclinical validation of actionable vulnerabilities</b> Christian Reinhardt, University Hospital Essen (GER)
<b>2:50</b>	<b>Discussion</b>
<b>3:00</b>	<b>Closing remarks</b> Farewell and Goodbye

Status April 2024. Subject to change

**SPONSORS - Thank you for the support**

In accordance with the recommendations of the German Medical Association, the Association of Scientific Medical Societies and the Voluntary Self-Regulation of the Pharmaceutical Industry (FSA Code of Conduct for Healthcare Professionals, Section 20 (5)), the contributions (net amounts, before deduction of costs) of the industry partnerships are disclosed. The above-mentioned companies are participating in the West German Lymphoma Symposium in return for services. Net amounts, before deduction of costs. AbbVie Deutschland GmbH & Co. KG, 50,000 € - Bristol-Myers Squibb GmbH & Co. KGaA, 20,000 € - Incyte Inc., 10,000 € - Lilly Deutschland GmbH, 50,000 € - Roche Pharma AG, 50,000 € - Takeda Pharma Vertrieb GmbH & Co. KG, 5,000 € - Status: 03/2024